首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   22217篇
  免费   2446篇
  国内免费   37篇
耳鼻咽喉   162篇
儿科学   761篇
妇产科学   816篇
基础医学   3067篇
口腔科学   572篇
临床医学   2581篇
内科学   4818篇
皮肤病学   339篇
神经病学   1676篇
特种医学   801篇
外科学   2682篇
综合类   724篇
一般理论   35篇
预防医学   2296篇
眼科学   340篇
药学   1971篇
  1篇
中国医学   11篇
肿瘤学   1047篇
  2021年   294篇
  2020年   193篇
  2019年   331篇
  2018年   362篇
  2017年   284篇
  2016年   296篇
  2015年   344篇
  2014年   497篇
  2013年   645篇
  2012年   962篇
  2011年   993篇
  2010年   566篇
  2009年   517篇
  2008年   882篇
  2007年   1030篇
  2006年   955篇
  2005年   922篇
  2004年   931篇
  2003年   839篇
  2002年   824篇
  2001年   757篇
  2000年   821篇
  1999年   687篇
  1998年   279篇
  1997年   249篇
  1996年   247篇
  1995年   255篇
  1994年   230篇
  1993年   208篇
  1992年   530篇
  1991年   543篇
  1990年   522篇
  1989年   521篇
  1988年   480篇
  1987年   493篇
  1986年   447篇
  1985年   413篇
  1984年   360篇
  1983年   291篇
  1982年   232篇
  1981年   190篇
  1979年   286篇
  1978年   282篇
  1977年   199篇
  1976年   205篇
  1975年   193篇
  1974年   210篇
  1973年   176篇
  1972年   202篇
  1970年   172篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc.  相似文献   
5.
6.
7.
8.
Partial nephrectomy is the mainstay of treatment for localized kidney cancer. A proportion of patients are upstaged post-operatively to locally advanced di  相似文献   
9.
Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to bleeding after trauma and post‐partum haemorrhage. One key issue for treatment success is early administration. While usually given intravenously, oral and intramuscular use would be useful in specific circumstances. Therefore, an understanding of TXA pharmacokinetics when given via different routes is valuable. The aim of this study was to perform an individual participant data meta‐analysis of pharmacokinetic studies with TXA given to healthy volunteers via different routes. We searched the following databases: PubMed, Web of Science, Wiley Online Library, Elsevier Science Direct and J‐STAGE. Individual subject data were extracted when available, otherwise arithmetic means were used. A population pharmacokinetic model was developed using nonlinear mixed effect modelling. Seven studies were included in the analysis with data from 10 patients for the IV route, six patients for the IM route and 114 patients for the oral route. The pharmacokinetics was ascribed to a two‐compartment model, and the main covariate was allometrically scaled bodyweight. Oral and IM bioavailabilities were 46 and 105%, respectively. For a 70 kg bodyweight, the population estimates were 7.6 L/h for clearance, 17.9 L for the volume of the central compartment, 2.5 L/h for the diffusional clearance and 16.6 L for the peripheral volume of distribution. Larger well‐designed studies are needed to describe the pharmacokinetics of TXA when given IM or as an oral solution before these can be recommended as alternatives to IV.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号